News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
312 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21900)
Month
January (4345)
February (4356)
March (4475)
April (4721)
May (4999)
June (4103)
July (3643)
August (3329)
September (4039)
October (5055)
November (4470)
December (3799)
Day
1 (119)
3 (12)
4 (242)
5 (269)
6 (241)
7 (243)
8 (78)
9 (2)
10 (3)
11 (232)
12 (312)
13 (213)
14 (243)
15 (110)
16 (8)
17 (9)
18 (85)
19 (267)
20 (246)
21 (243)
22 (113)
23 (7)
24 (12)
25 (220)
26 (276)
27 (239)
28 (312)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Business
Abpro And Njcttq Enter Into Partnership For Development Of Multiple Novel Bispecific Antibodies
Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties
February 28, 2019
·
4 min read
Noxxon To Present Latest Clinical Data From Nox-a12 / Keytruda® Combination Trial At The 2019 Aacr Annual Meeting
NOXXON Pharma N.V. announced that the company will present the latest safety, survival and more mature clinical data in patients treated with the CXCL12 inhibitor NOX-A12 in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients.
February 28, 2019
·
2 min read
Previous
32 of 32
